Liraglutide Dosing
For type 2 diabetes (Victoza), initiate liraglutide at 0.6 mg subcutaneously once daily, increase to 1.2 mg after 1 week, and titrate to a maximum of 1.8 mg daily as tolerated; for obesity (Saxenda), follow the same weekly titration schedule but continue to a target dose of 3.0 mg daily. 1, 2
Type 2 Diabetes Dosing (Victoza)
Initiation and Titration:
- Week 1: Start at 0.6 mg subcutaneously once daily
- Week 2 onward: Increase to 1.2 mg daily
- Maintenance: 1.2-1.8 mg daily (titrate to 1.8 mg if additional glycemic control needed)
The 0.6 mg starting dose is not therapeutic—it exists solely to minimize gastrointestinal side effects during initiation 3. Inject at any time of day, independent of meals 1.
Important: No renal dose adjustments are required for liraglutide, making it advantageous for patients with diabetic kidney disease 1. This contrasts sharply with exenatide (avoid if CrCl <30) and lixisenatide (avoid if CrCl <15).
Obesity Dosing (Saxenda)
Extended Titration Schedule:
- Week 1: 0.6 mg daily
- Week 2: 1.2 mg daily
- Week 3: 1.8 mg daily
- Week 4: 2.4 mg daily
- Week 5 onward: 3.0 mg daily (target dose)
Pediatric patients (≥12 years): Follow the same escalation but may require up to 8 weeks for titration. If 3.0 mg is not tolerated, may reduce to 2.4 mg as maintenance dose 2.
Critical Decision Points
Discontinuation Criteria:
For adults with obesity: Discontinue if <4% weight loss at 16 weeks—continued treatment unlikely to produce meaningful results 2.
For pediatric patients: Discontinue if <1% BMI reduction after 12 weeks on maintenance dose 2.
For type 2 diabetes: The 2025 AACE guidelines demonstrate that liraglutide 3.0 mg produces superior weight loss (-5.8% vs -1.5% placebo) while achieving robust A1C reduction (-1.3% vs -0.3% placebo) in patients with both diabetes and obesity 4.
Administration Essentials
- Route: Subcutaneous injection in abdomen, thigh, or upper arm
- Timing: Once daily, any time, with or without food
- Rotation: Change injection sites within same region to prevent cutaneous amyloidosis 2
- Missed dose: Resume next scheduled dose; do not double up
- Lapse >3 days: Restart at 0.6 mg and re-titrate to minimize GI symptoms 2
Common Pitfalls
Nausea management: The weekly dose escalation is specifically designed to mitigate nausea, which is typically transient 3, 4. If patients cannot tolerate dose increases, delay escalation by approximately one additional week rather than abandoning therapy 2.
Hypoglycemia risk: When combined with sulfonylureas or insulin, consider reducing those agents' doses—liraglutide itself carries minimal hypoglycemia risk due to glucose-dependent insulin secretion 3.
Cardiovascular benefit: The 1.8 mg dose (not 3.0 mg) demonstrated cardiovascular risk reduction in the LEADER trial, reducing MACE in patients with type 2 diabetes and established CVD 4. This makes liraglutide particularly valuable for patients with both diabetes and cardiovascular disease.